A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase I Trial Assessing the Pharmacokinetic Profile, Safety and Tolerability of a Continuous Daily Dosing Regimen of Active IMP in Healthy Volunteers

MedinCell S.A1 site in 1 country24 target enrollmentSeptember 22, 2020

ConditionsCovid19

InterventionsIvermectin Placebo

DrugsIvermectin Placebo

Overview

Phase: Phase 1
Intervention: Ivermectin
Conditions: Covid19
Sponsor: MedinCell S.A
Enrollment: 24
Locations: 1
Primary Endpoint: Pharmacokinetic Concentrations - (Time to Reach Cmax [Tmax])
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

An early stage trial to check how safe and tolerable, as well as how the body handles continuous daily use of Active IMP over 28 days in healthy volunteers.

Detailed Description

Detailed information restricted because this is a Phase 1 clinical trial.

Registry

clinicaltrials.gov

Start Date

September 22, 2020

End Date

March 9, 2021

Last Updated

4 years ago

Study Type

Interventional

Study Design

Sequential

Sex

Male

Investigators

Sponsor

MedinCell S.A

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subject is male of any ethnic origin.
•Subject is aged between 18 to 45 years, inclusive.
•Subject has a body mass index (BMI) of 18.5 to 32.0 kg/m2, inclusive.
•Subject is ≥50 kg.
•Negative reverse transcription polymerase chain reaction (RT-PCR) Test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at Screening and negative lateral flow immunoassay test for SARS-CoV-2 at Day -
•Healthy as determined by a responsible physician, based on medical evaluation including medical history, physical examinations, neurological examinations, concomitant medication, vital signs, 12-lead ECG and clinical laboratory evaluations.
•Male subjects must use a condom during the study and for 3 months after their final dose of study medication, if their partner is a woman of childbearing potential. In addition, their female partner of childbearing potential must use an additional method of highly effective contraception from first dosing until 3 months following final dosing.

Exclusion Criteria

•Clinically relevant history of abnormal physical or mental health (defined as any subject requiring medical, psychological or pharmacotherapeutic intervention for mental illness) interfering with the study as determined by medical history and physical examinations obtained during Screening and Day -1 as judged by the Investigator (including \[but not limited to\], neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder).
•Any other concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study as outlined in this Protocol, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study.
•Evidence of previous SARS-CoV-2 infection from medical history.
•Ophthalmologic disorder (moderate and sever retina or optic nerve pathology; cataracts excluded).
•Subjects with a diagnosis of asthma or any other respiratory conditions.
•A neurologic disorder that may compromise blood brain barrier permeability (stroke within 90 days, brain tumour, multiple sclerosis, or other neuroinflammatory condition, a neurodegenerative disorder, epilepsy) or history of seizures.
•Positive test for hepatitis B surface antigen (HBsAg), anti-hepatitis C antibody (anti-HCV) or human immunodeficiency virus I and II (anti-HIV I/II) at Screening.
•The subject has participated in a clinical study and has received a medication or a new chemical entity within 3 months or 5 half-lives (whichever is longer) prior to first dosing of current study medication.
•Use of any drugs that are known substrates of CYP3A4, P-glycoprotein (P-gp) from within 4 weeks of Screening and unable to refrain from them until the end of the study (e.g., rifampicin, quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat). Use of critical CYP3A4 substrate drugs such as warfarin or coumarin anticoagulants.
•Recent or expected microfilaricidal drug use, including ivermectin, or travel history to areas that are endemic for Loa loa or onchocerciasis (Angola, Cameroon, Central African Republic, Chad, Democratic Republic of Congo, Ethiopia, Equatorial, Guinea, Gabon, Republic of Congo, Nigeria and Sudan).